CHRU Lille
CHRU Lille
Lille, France32 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Met Non Small Cell Cancer Registry (MOMENT) | cancer, neoplasm | Recruiting | Not stated | 2026-10-02 | NCT05376891 | |
| Phase IIa Trial of Anti-CD19 CAR T-Cells in Systemic Sclerosis Resistant to Immunosuppressive Therapy | Skin and Connective Tissue Diseases, connective tissue disorder, skin disorder, systemic sclerosis | Active, not recruiting | Phase 2 | 2026-09-16 | NCT07493395 | |
| Personalized Circulating DNA Follow-up in Melanoma (PERCIMEL) | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Active, not recruiting | Not applicable | 2026-09-01 | NCT04866680 | |
| A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab | Cryoglobulinemic vasculitis | Recruiting | Phase 2 | 2026-08-31 | NCT07268521 | |
| Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-MOG Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial | autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myelin oligodendrocyte glycoprotein antibody-associated disease | Recruiting | Phase 3 | 2026-08-31 | NCT05545384 | |
| DEWI: Watch-and-Wait With Dostarlimab in Localized dMMR/MSI-H Gastric/GEJ Adenocarcinoma Phase II Study | gastric adenocarcinoma, gastroesophageal junction adenocarcinoma | Recruiting | Phase 2 | 2026-08-26 | NCT06059495 | |
| Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 2 | 2026-07-07 | NCT06552234 | |
| PARa-aOrtic LymphAdenectomy in Locally Advanced Cervical Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, adenocarcinoma, adenosquamous carcinoma, carcinoma, cervical carcinoma, cervix disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, mixed neoplasm, neoplasm, uterine disorder | Recruiting | Phase 3 | 2026-07-07 | NCT05581121 | |
| Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up | Head and Neck Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, thyroid gland disorder, thyroid tumor | Recruiting | Phase 3 | 2026-06-25 | NCT04290663 | |
| A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse." | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 2 | 2026-06-15 | NCT04998786 | |
| Chronic Hypertension and Acetyl Salicylic Acid in Pregnancy | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Death, Female Urogenital Diseases and Pregnancy Complications, Fetal Diseases, Obstetric Labor Complications, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Perinatal Death, Urogenital Diseases, fetal growth restriction, hereditary endocrine growth disease, hypertension, pregnancy-induced, placenta disorder, placental abruption, preeclampsia, pregnancy disorder | Recruiting | Phase 3 | 2026-06-12 | NCT04356326 | |
| Phase II Study Evaluating Safety and Efficacy of Tislelizumab for Elderly Patients Unfit for Chemotherapy, With Advanced Esophageal Squamous-cell Carcinoma | Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal disorder, esophageal squamous cell carcinoma, neoplasm, squamous cell carcinoma, squamous cell neoplasm | Recruiting | Phase 2 | 2026-05-20 | NCT07205731 | |
| Maintaining or Stopping Immunosuppressive Therapy in Patients With ANCA Vasculitis and End-stage Renal Disease | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Urogenital Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, chronic renal failure syndrome, immune system disorder, kidney disorder, kidney failure, necrotizing vasculitis, skin disorder, skin vascular disease, urinary system disorder, vascular disorder, vasculitis | Active, not recruiting | Phase 3 | 2026-03-20 | NCT03323476 | |
| Study of the Determinants of Coronary Atherosclerosis in Familial Hypercholesterolemia (ATHERO-FH Study) | Arterial Occlusive Diseases, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, arteriosclerosis disorder, atherosclerosis, cardiovascular disorder, familial hypercholesterolemia, hereditary disease, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease, vascular disorder | Recruiting | Not applicable | 2026-03-19 | NCT06960902 | |
| Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis | Acute Exacerbation of Idiopathic Pulmonary Fibrosis | Recruiting | Phase 3 | 2026-03-02 | NCT05674994 | |
| Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Recruiting | Phase 2 | 2026-01-30 | NCT05917405 | |
| Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, squamous cell carcinoma | Recruiting | Not applicable | 2026-01-02 | NCT04528420 | |
| Creation of a Register of Patients With Neonatal-onset Epileptic Encephalopathy | brain disorder, central nervous system disorder, epilepsy, nervous system disorder | Recruiting | Not stated | 2025-11-20 | NCT04802135 | |
| Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. | Metastatic Pancreatic Adenocarcinoma | Active, not recruiting | Phase 2 | 2025-07-25 | NCT04348045 | |
| OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm, pancreatic ductal adenocarcinoma | Active, not recruiting | Phase 2 | 2025-07-25 | NCT03806309 | |
| Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. | Advanced Biliary Tract Carcinoma | Active, not recruiting | Phase 2 | 2025-07-23 | NCT03704480 | |
| Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2025-07-01 | NCT05310643 | |
| Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France | Blood-Borne Infections, DNA Virus Infections, Digestive System Diseases, Digestive System Neoplasms, Fibrosis, Fibrosis, Liver, Flaviviridae infectious disease, Hepadnaviridae infectious disease, Infections, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, RNA Virus Infections, adenocarcinoma, carcinoma, cirrhosis of liver, epithelial neoplasm, hepatitis, hepatitis B virus infection, hepatitis C virus infection, hepatitis D virus infection, hepatocellular carcinoma, infectious disease, liver disorder, neoplasm, viral hepatitis, viral infectious disease | Not yet recruiting | Not applicable | 2025-06-26 | NCT07038863 | |
| Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma. | Genomic Instability, Microsatellite Instability, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Active, not recruiting | Phase 2 | 2025-06-15 | NCT04006262 | |
| Two Combination Treatment Regimens of Nivolumab and Ipilimumab in Patients With dMMR and / or MSI mCRC. | Colorectal Cancer Metastatic; MSI-H Colorectal Cancer | Active, not recruiting | Phase 2 | 2025-06-13 | NCT04730544 |